The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Welcome to The Aggressive & Diffuse Large B-Cell Lymphoma Channel

VJHemOnc shares important updates on aggressive & diffuse large B-cell lymphoma, a common lymphoid malignancy in adults accounting for 30% of malignant lymphomas. The Aggressive & Diffuse Large B-Cell Lymphoma Channel provides unique perspectives from distinguished experts around the world in the form of video interviews, podcasts, and roundtable discussions.

Explore the latest research into novel therapies including CAR-T cells, immunomodulators, and antibody-drug conjugates on The Aggressive & Diffuse Large B-Cell Lymphoma Channel.

Burkitt
Lymphoma

View all

1:19

Insights into the management of Burkitt lymphoma: the need to improve frontline treatment

Ariela Noy • 3 Sep 2025

1:24

Challenges associated with double-hit R/R Burkitt lymphoma & novel therapies being explored

Ariela Noy • 3 Sep 2025

2:37

The outcomes of autoSCT and alloSCT in R/R Burkitt lymphoma: an analysis of EBMT Registry data

Lorenz Thurner • 11 Jun 2025

4:39

A novel approach: targeting MYC for the treatment of acute leukemias

Michael Andreeff • 18 Mar 2025

Diffuse Large
B-Cell Lymphoma

View all

4:41

Intrathecal rituximab plus dexamethasone in B-cell malignancies with CNS involvement

Maher Salamoon • 26 Jun 2024

2:45

The value of axi-cel as a second-line treatment in R/R LBCL

Paolo Cortesi • 24 Apr 2024

1:24

Employing CAR-T therapies in earlier lines of large B-cell lymphoma treatment

Paolo Cortesi • 24 Apr 2024

1:36

Loncastuximab tesirine as a consolidation strategy post-CAR T-cell therapy in DLBCL

Paolo Strati • 10 Dec 2023

The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.